thiophenes has been researched along with Cognition Disorders in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Hort, J; Klimova, B; Kuca, K; Nepovimova, E; Novotny, M; Oleksak, P; Patocka, J; Pavlik, J; Valis, M | 1 |
| Ayuga, Á; Gómez-Arguelles, JM; Marey, J; Moya, M; Ramírez, F; Salvador, A; Valldeoriola, F | 1 |
| Das, I; Jeon, SK; Linden, DJ; Lorenzi, H; Park, JM; Reeves, RH; Shin, JH; Worley, PF | 1 |
| Bai, HY; Chisaka, T; Horiuchi, M; Iwanami, J; Jing, F; Kan-no, H; Min, LJ; Mogi, M; Nakaoka, H; Ohshima, K; Tsukuda, K; Wang, XL | 1 |
| Bauer, LO; Dgetluck, N; Gawryl, M; Hilt, DC; Palfreyman, M; Preskorn, SH | 1 |
| Fujita, Y; Futamura, T; Hashimoto, K; Kikuchi, T; Ohgi, Y; Yoshimi, N | 1 |
| Futamura, T; Hashimoto, K; Yoshimi, N | 1 |
| Dgetluck, N; Gawryl, M; Hilt, DC; Keefe, RS; Koenig, G; Lombardo, I; Meltzer, HA; Moebius, HJ | 1 |
| Atkins, CM; Carballosa, MM; Dietrich, WD; Freund, JE; Furones, C; Gurney, ME; Sikah, KE; Titus, DJ; Wilson, NM | 1 |
| Berrou, JP; Goch, JH; Hanon, O; Nádházi, Z; Negre-Pages, L; Pathak, A; Petrella, R; Sedefdjian, A; Sévenier, F; Shlyakhto, EV | 1 |
| Chuang, TT; Gil-Bea, FJ; Marcos, B; Ramirez, MJ | 1 |
| Guàrdia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Montelongo-Pedraza, P; Padrós Blázquez, F; Peró-Cebollero, M | 1 |
| Gómez-Carbajal, L; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Joan, GO; Peña-Olvira, M; Villuendas-González, E | 1 |
| Fukushima, T; Hattori, H; Hoki, S; Iwakami, N; Nakada, Y; Nakagawa, M; Nakamura, A; Narita, H; Terashima, N; Yamaguchi, H | 1 |
| Dundon, K; Mease, PJ; Sarzi-Puttini, P | 1 |
| Boulouard, M; Da Silva Costa-Aze, V; Dauphin, F; Quiedeville, A | 1 |
| Hansen, T; Katona, C; Olsen, CK | 1 |
| Ardid, D; Chapuy, E; Eschalier, A; Grégoire, S; Michaud, V | 1 |
| Maubach, K | 1 |
| Hanon, O; Negre-Pages, L; Pathak, A; Sevenier, F | 1 |
| Dinkel, JJ; Mohs, RC; Raskin, J; Rotz, BT; Sheikh, J; Siegal, A; Wiltse, CG; Xu, J | 1 |
| Ram, CV; Rudmann, MA | 1 |
| Shlyakhto, E | 1 |
| Brass, EP; Cutler, NR; Jones, D; Moore, M; Polinsky, R; Sramek, JJ; Veroff, AE; Wardle, TS | 1 |
| Münch, G; Palm, D; Riederer, P; Schindler, U; Schinzel, R; Schraven, E; Taneli, Y | 1 |
| Brandeis, R; Fisher, A; Gurwitz, D; Haring, R; Heldman, E; Karton, I; Levy, A; Pittel, Z; Sapir, M | 1 |
| Brandeis, R; Dachir, S; Fisher, A; Heldman, E; Karton, I; Levy, A; Pittel, Z; Sapir, M | 1 |
5 review(s) available for thiophenes and Cognition Disorders
| Article | Year |
|---|---|
Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and Neurodegeneration.
Topics: Animals; Cognition Disorders; Humans; Muscarinic Agonists; Neurodegenerative Diseases; Neuropharmacology; Pharmaceutical Preparations; Quinuclidines; Thiophenes | 2021 |
Pharmacotherapy of fibromyalgia.
Topics: Analgesics; Chronic Pain; Clinical Trials as Topic; Cognition Disorders; Cyclopropanes; Duloxetine Hydrochloride; Fatigue; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Milnacipran; Mood Disorders; Pain Management; Pregabalin; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders; Syndrome; Thiophenes; Treatment Outcome | 2011 |
GABA(A) receptor subtype selective cognition enhancers.
Topics: Alzheimer Disease; Animals; Benzodiazepines; Cognition; Cognition Disorders; Disease Models, Animal; GABA Agonists; Haplorhini; Hippocampus; Humans; Mice; Mice, Transgenic; Receptors, GABA-A; Thiazoles; Thiophenes | 2003 |
Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Cognition Disorders; Female; Humans; Hypertension; Imidazoles; Male; Sensitivity and Specificity; Severity of Illness Index; Stroke; Survival Analysis; Systole; Thiophenes; Treatment Outcome | 2007 |
Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Dementia, Vascular; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Neuropsychological Tests; Rats; Stroke; Thiophenes | 2007 |
7 trial(s) available for thiophenes and Cognition Disorders
| Article | Year |
|---|---|
Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Topics: Adolescent; Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Cognition; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Evoked Potentials; Female; Humans; Male; Middle Aged; Quinuclidines; Schizophrenia; Thiophenes; Treatment Outcome; Young Adult | 2014 |
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Topics: Adolescent; Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinuclidines; Schizophrenia; Schizophrenic Psychology; Thiophenes; Treatment Outcome; Young Adult | 2015 |
Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
Topics: Acrylates; Aged; Antihypertensive Agents; Blood Pressure; Cognition; Cognition Disorders; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Male; Middle Aged; Neuropsychological Tests; Thiophenes; Treatment Outcome | 2008 |
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Sulfides; Thiophenes; Vortioxetine | 2012 |
Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Topics: Age Factors; Aged; Antidepressive Agents; Back Pain; Cognition Disorders; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Geriatric Assessment; Humans; Male; Neuropsychological Tests; Pain; Pain Measurement; Placebos; Psychiatric Status Rating Scales; Secondary Prevention; Thiophenes; Treatment Outcome | 2007 |
Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Dementia, Vascular; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Neuropsychological Tests; Rats; Stroke; Thiophenes | 2007 |
Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans.
Topics: Adult; Analysis of Variance; Cholinergic Agents; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Humans; Imidazoles; Male; Saliva; Scopolamine; Thiophenes | 1995 |
16 other study(ies) available for thiophenes and Cognition Disorders
| Article | Year |
|---|---|
The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Cognition Disorders; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Product Surveillance, Postmarketing; Retrospective Studies; Sleep Wake Disorders; Spain; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome; Urination Disorders | 2018 |
Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model.
Topics: Animals; Behavior, Animal; Cerebellum; Cognition Disorders; Cyclohexylamines; Disease Models, Animal; Down Syndrome; Electrophysiology; Hedgehog Proteins; Hippocampus; Long-Term Synaptic Depression; Male; Maze Learning; Memory; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Neuronal Plasticity; Phenotype; Purkinje Cells; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission; Thiophenes | 2013 |
Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Cerebrovascular Circulation; Cognition Disorders; Cytokines; Diabetes Mellitus, Type 2; Drug Synergism; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Maze Learning; Memantine; Mice; Receptor, Angiotensin, Type 2; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Thiophenes | 2014 |
Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.
Topics: Animals; Cognition Disorders; Male; Mice; Mice, Inbred ICR; Phencyclidine; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Thiophenes | 2014 |
Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator.
Topics: Analysis of Variance; Animals; Cognition Disorders; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Mice; Mice, Inbred C57BL; Quinolones; Recognition, Psychology; Serotonin Agents; Social Behavior; Thiophenes | 2015 |
Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor.
Topics: Animals; Brain Injuries, Traumatic; Cognition Disorders; Conditioning, Classical; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Fear; Hippocampus; Interleukin-1beta; Long-Term Potentiation; Male; Maze Learning; Memory, Short-Term; Nerve Tissue Proteins; Phenylacetates; Phosphodiesterase 4 Inhibitors; Rats; Rats, Sprague-Dawley; Reaction Time; Thiophenes; Tumor Necrosis Factor-alpha | 2016 |
Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Drug Administration Schedule; Drug Therapy, Combination; Galantamine; Male; Maze Learning; Motor Activity; Rats; Rats, Wistar; Receptors, Serotonin; Scopolamine; Serotonin Antagonists; Sulfonamides; Thiophenes; Yawning | 2008 |
Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Topics: Adult; Antidepressive Agents; Citalopram; Cognition Disorders; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Reference Values; Selective Serotonin Reuptake Inhibitors; Thiophenes; Wechsler Scales | 2010 |
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Attention Deficit Disorder with Hyperactivity; Citalopram; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Executive Function; Female; Humans; Male; Neuropsychological Tests; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2010 |
T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice.
Topics: Alzheimer Disease; Animals; Cognition Disorders; Hippocampus; Maleates; Mice; Mice, Transgenic; Movement Disorders; Neuroprotective Agents; Synaptophysin; tau Proteins; Thiophenes | 2011 |
5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice.
Topics: Animals; Avoidance Learning; Cholinergic Antagonists; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Memory Disorders; Memory, Short-Term; Mice; Receptors, Serotonin; Scopolamine; Serotonin Antagonists; Sulfonamides; Thiophenes | 2012 |
Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin.
Topics: Affective Symptoms; Amines; Analgesics; Animals; Antidepressive Agents; Cognition; Cognition Disorders; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Emotions; Gabapentin; gamma-Aminobutyric Acid; Male; Neuralgia; Rats; Rats, Sprague-Dawley; Thiophenes; Treatment Outcome | 2012 |
Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cognition; Cognition Disorders; Female; Humans; Hypertension; Imidazoles; Longitudinal Studies; Male; Middle Aged; Multicenter Studies as Topic; Neuropsychological Tests; Observation; Patient Selection; Receptor, Angiotensin, Type 1; Research Design; Thiophenes | 2007 |
The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation.
Topics: Aging; Alzheimer Disease; Cognition Disorders; Glycation End Products, Advanced; Glycosylation; Humans; Macromolecular Substances; Nerve Tissue Proteins; Piperazines; Psychotropic Drugs; Thiophenes | 1994 |
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Binding, Competitive; Cognition Disorders; Copper; Disease Models, Animal; Male; Memory; Mice; Motor Activity; Parasympathomimetics; Pilocarpine; Quinuclidines; Quinuclidinyl Benzilate; Receptors, Muscarinic; Thiophenes | 1991 |
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats.
Topics: Alzheimer Disease; Animals; Aziridines; Behavior, Animal; Choline; Cognition Disorders; Disease Models, Animal; Drug Design; Male; Molecular Structure; Parasympathomimetics; Quinuclidines; Rats; Rats, Inbred Strains; Receptors, Muscarinic; Thiophenes | 1989 |